Michael Makris։ New NEJM Paper Reports Results of Mim8 in Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn about a recent article by Maria Elisa Mancuso et al, published in The New England Journal of Medicine (NEJM), adding։
”The Mim8 results paper was published today in the New England Journal of Medicine.
Mim8 works in the same way and is a direct competitor to emicizumab (Hemlibra).
The introduction of emicizumab has been the most impactful change in hemophilia care in the last 20-25 years.
Both Mim8 and emicizumab are bispecific antibodies. Is one better than the other in terms of efficacy? Only a randomised trial will tell us this, but nobody will do such a trial. I expect there will be lots of papers comparing the two products in a non-randomised way, with all the limitations that they bring.
In most countries, the introduction of a second similar drug will result in competition and lower prices, but I doubt this will be the case in the US.
The PDF of the paper is behind a paywall, but here is the graphical summary.”
Title: Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors
Authors: Maria Elisa Mancuso, Anthony K.C. Chan, Chandrakala Shanmukhaiah, Chuhl Joo Lyu, Joanna Zdziarska, Johnny Mahlangu, Lize F.D. van Vulpen, Pratima Chowdary, Renchi Yang, Steven R. Lentz, Tadashi Matsushita, Wan Hui Ong Clausen, Ilgiz Rakhmatullin, Johannes Oldenburg
Other posts featuring Michael Makris on Hemostasis Today.
-
Sep 15, 2026, 15:29Abdul Muqtadir Abbasi: Recognizing Thalassemia Trait Is Essential for Every Physician
-
Sep 15, 2026, 15:17Shehab Mohamed: A New Regional Consensus on HLH Diagnosis and Management
-
Sep 15, 2026, 15:17Sheharyar Raza: Managing Randomness in Artificial Intelligence for Transfusion Medicine
-
Sep 15, 2026, 15:00Sarah Wachtman: Modeling AAV-Based Gene Therapy for Hemophilia A Using Pediatric Liver Organoids
-
Sep 15, 2026, 15:00Ashenafi Tazebew Amare: From Blood Donation to Innovation and Patient Access
-
Sep 15, 2026, 14:56Glanzmann Thrombasthenia Beyond Platelet Transfusion
-
Sep 15, 2026, 14:55Christina Pohlman: The Hidden Complexity of Warfarin Therapy in APS
-
Sep 15, 2026, 14:44Consuela A. Albright: Building a More Connected Sickle Cell Care System
-
Sep 15, 2026, 14:43Andrew Jackson: Cyanosis as a Clue to Central Venous Obstruction